Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBsolvMIR vs Heparin in islet transplantation for type 1 diabetes
2016-001867-35Phase 2Terminated
- Sponsor
- TikoMed
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ilb in diabetes mellitus type 1 (T1D) (2 arms), sponsored by TikoMed. Primary endpoint: Bleeding events after islet transplantation. Started Sep 2018; status: terminated.
02
Drugs
ilb
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2016-001867-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001867-35.